True Wealth Design’s Inhibikase Therapeutics IKT Stock Holding History

True Wealth Design’s Portfolio IKT Stock Details IKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.01K	Buy	499 +456	+1,060%	+$816	﹤0.01%	1971
2026 Q1	$73	Buy	+43	New	+$76	﹤0.01%	2515

Other funds holding IKT

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

SIC

SJS Investment Consulting Sylvania, Ohio $919M AUM 23.4% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

True Wealth Design's IKT Position: Q2 2026 in Review

True Wealth Design increased its Inhibikase Therapeutics (IKT) stake by 1,060% in Q2 2026, buying an estimated $816 and bringing the position to 499 shares worth $1.01K. The position accounts for ﹤0.01% of the portfolio, ranked #1971.

True Wealth Design first reported a position in IKT in Q1 2026 and has held it in 2 quarters since. 5 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

True Wealth Design held 499 shares of Inhibikase Therapeutics worth $1.01K as of Q2 2026.
True Wealth Design bought 456 Inhibikase Therapeutics shares in Q2 2026, an estimated $816.
Inhibikase Therapeutics made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #1971 holding.
True Wealth Design first reported a position in Inhibikase Therapeutics in Q1 2026 and has held it in 2 quarters since.
5 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.